Discover our companies, technologies and events from OUI
No images? Click here
MEDTECH
Theolytics – first trials of new medicine for ovarian cancer
Theolytics, an Oxford-based spinout, is revolutionising cancer treatment with its innovative use of oncolytic viruses. By testing these viruses on real patient tumour samples, the company is developing highly targeted therapies that spare healthy tissue, offering new hope for more effective cancer treatments.
SOFTWARE
How OUI drives impact through software commercialisation in drug discovery and healthcare
Oxford University Innovation (OUI) is making significant strides in software commercialisation, licensing cutting-edge technologies like Virtual Assay, SAbBox, and FMRIB Software Library to companies worldwide. These innovations, developed by Oxford academics, are revolutionising drug discovery, antibody development, and neuroimaging, creating both economic and societal impact while supporting research across universities.
STARTUP NEWS
adh_we - Helping brands navigate neurodiversity
adh_we, an Oxford-based startup, is transforming consumer experiences by focusing on neuro-inclusive design. Co-founded by Olly and Amelia Markeson, the company helps brands like Versace and Goodwill create more inclusive, accessible experiences for neurodivergent consumers.
STARTUP INCUBATOR
BioFragment winners
Oxford spinout BioFragment recently secured an award at Stage Two, Europe's largest university pitch competition. BioFragment's innovative approach to sustainable drug discovery impressed a panel of industry leaders, accelerating their mission to reshape biotechnology.
OTHER NEWS
The University of Oxford and the Ellison Institute of Technology (EIT) form strategic alliance
The University of Oxford and the Ellison Institute of Technology (EIT) have established a long-term strategic partnership backed by a £130 million investment. The alliance aims to foster innovation across key global challenges such as health, climate change, and AI, combining Oxford’s academic excellence with EIT’s cutting-edge research and resources.
Licence Agreement Spotlight
Discover some of the people behind the R21 / Matrix-M™ malaria vaccine and how the team at Oxford University Innovation supported the licence agreement to co-develop this life-saving vaccine with the Serum Institute of India.
INVESTMENT NEWS
JPM OUI investor event
We hosted our second Oxford University Innovation Transatlantic Healthcare networking event during this year’s JPM Healthcare Conference in San Francisco. We were delighted our spinout leadership and existing and potential investors joined us to discover our latest spinout companies. Special thanks to our spinout speakers and event partners Womble Bond Dickinson (US) LLP and HGF Ltd.
INVESTMENT NEWS
EY evaluating Covid testing programme to implement learnings for future pandemics / impact on public health
Oxford University Innovation, in partnership with Ernst & Young (EY), conducted an independent evaluation of England’s COVID-19 testing programme for the UK Health Security Agency, showcasing the effectiveness of testing in identifying cases and mitigating public health impacts. This collaboration provided evidence-based recommendations for future pandemic preparedness, highlighting the importance of equitable access, multidisciplinary approaches, and robust health data infrastructure.
CLINICAL OUTCOMES
Measuring patient health-related quality of life in nutrition, dietetics, and gastroenterological conditions
Oxford University Innovation's Clinical Outcomes team offers validated Clinical Outcome Assessments (COAs) to improve patient care in gastroenterology and nutrition. These tools, such as the Coeliac Disease Assessment Questionnaire and the Nutrition and Dietetic Patient Outcomes Questionnaires, provide valuable insights into patients' health perceptions, the impact of their conditions, and the effectiveness of treatments, supporting more patient-centred care.
Independent review of spinouts
Oxford University Innovation is supporting the UK government’s efforts to boost spinout growth in the UK. With a focus on turning world-leading research into successful companies, we aim to implement the recommendations from the Independent Review of Spinouts to create a thriving, nationwide ecosystem.
OIS NEWS
OIS events in the pipeline and membership drive
The Oxford Innovation Society (OIS) underwent an exciting transformation in 2024, offering a broader range of events designed to foster collaboration and connect members. Beyond traditional gala dinners, the new format includes investor forums in Oxford, London, and the USA, as well as networking opportunities at major healthcare conferences. Looking ahead, 2025 will bring even more opportunities for Oxford's entrepreneurs to engage with industry, investors and government, with events like the Social Ventures Showcase.
TECHNOLOGY PROFILES
Catalytic amplification of faradic redox signal
This electrochemical sensing technology detects proteins by tagging them with biotin, capturing them with specific antibodies, and labelling them with amplifying enzymes (poly(HRP)) to enhance electrochemical signals.
Predictive biomarkers for chemotherapy cardiotoxicity
Predictive SNPs identified from GWAS studies and subsequently validated that predict the likelihood of cardiac related toxicity during 5-fluorouracil (5-FU) or Capecitabine treatment for colorectal, gastric, or breast cancer.
Method for diagnosis of Early Onset Pre-eclampsia (EOPE)
Pre-eclampsia is a leading cause of maternal and perinatal complications globally, yet early identification of high-risk women remains challenging. Researchers at Oxford have developed an innovative diagnostic method that improves early detection and offers significant advantages over existing approaches, potentially transforming clinical care and outcomes for at-risk pregnancies.
OUI NEWS
Investors in People – Gold accreditation
Oxford University Innovation (OUI) has earned the prestigious 'We Invest in People' Gold accreditation from Investors in People, placing it in the top 28% of organisations for workplace culture. This recognition highlights OUI's dedication to fostering a collaborative and supportive environment.
